Koman A, et al. - Researchers examined the value of normalization of hypercalcemia with short-term medical treatment in predicting the effects of parathyroidectomy and in guiding surgical decision-making. In this study, 110 patients [median age: 62 years; 91 women] who received calcimimetic treatment for 4 weeks before parathyroidectomy (30–60 mg daily) were made to undergo a panel of tests assessing various aspects of quality of life (European Organisation and Treatment of Cancer QLQ-C30 core questionnaire, Hospital Anxiety and Depression Scale and Positive State of Mind questionnaire), cognitive function (Montreal Cognitive Assessment) and muscle strength (timed-stands test). Normalization of calcium levels and improvements in quality-of-life parameters were observed in correlation with the receipt of calcimimetic treatment. Significantly shortened time spent on the timed-stands test was evident. During treatment with calcimimetic, 11 of 38 participants with a baseline Montreal Cognitive Assessment score below 26, indicating mild cognitive impairment, reached scores of at least 26. They observed a good correlation between improvements during treatment with calcimimetic and postoperative outcomes (positive predictive values 74%–96%). The method described in this work may assist in surgical decision-making for patients with primary hyperparathyroidism and non-disease-specific symptoms by prognosticating the consequences of normalization of hypercalcemia.